CNAT - Conatus Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.3800
+0.0020 (+0.53%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.3780
Open0.3800
Bid0.3702 x 1000
Ask0.3763 x 800
Day's Range0.3620 - 0.4044
52 Week Range0.2500 - 5.8900
Volume1,776,469
Avg. Volume747,233
Market Cap12.605M
Beta (3Y Monthly)2.25
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Conatus Pharmaceuticals Reports Second Quarter 2019 Financial Results and Program Updates

    SAN DIEGO, Aug. 06, 2019 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the quarter and six months ended June 30, 2019, and provided.

  • GlobeNewswire

    Conatus to Explore Strategic Alternatives and Implement Restructuring Plan

    Conatus Pharmaceuticals Inc. (CNAT) today announced that the company has engaged Oppenheimer & Co., Inc., as its financial advisor to assist in the exploration and evaluation of strategic alternatives to enhance shareholder value. In order to extend its resources, Conatus is implementing a restructuring plan that includes reducing staff by approximately 40% and suspending development of its inflammasome disease candidate, CTS-2090. The company has updated its financial guidance and is projecting a year-end 2019 net balance of cash, cash equivalents and marketable securities of between $10 million and $15 million.

  • GlobeNewswire

    Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis

    Conatus Pharmaceuticals Inc. (CNAT) today announced that top-line results from the company’s ENCORE-LF clinical trial of emricasan did not meet its primary endpoint and the company is discontinuing further treatment of patients enrolled in the ENCORE-LF clinical trial.  Also, results from the 24-week extension in the company’s ENCORE-PH clinical trial of emricasan were consistent with results from the initial 24-week treatment period and did not meet predefined objectives. Conatus will continue to work with its partner Novartis on ensuring that all remaining obligations related to the emricasan program are fulfilled. The randomized, double-blind ENCORE-LF Phase 2b clinical trial, initiated in the second quarter of 2017, enrolled 217 patients with decompensated NASH cirrhosis.

  • GlobeNewswire

    Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis

    Conatus Pharmaceuticals Inc. (CNAT) today announced a new publication1 in Hepatology Communications detailing results following seven-day treatment with emricasan, the company’s first-in-class pan-caspase inhibitor, in rats with advanced cirrhosis including increased portal pressure induced by chronic carbon tetrachloride administration. Portal pressure was significantly reduced in emricasan-treated rats relative to vehicle-treated control animals. Reduced portal pressure was associated with significantly better liver function, reduced liver inflammation, and reduced fibrosis.

  • GlobeNewswire

    Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

    Conatus Pharmaceuticals Inc. (CNAT) announced today that the company’s late-breaker oral presentation at The International Liver Congress™ 2019, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 10-14, was also selected by EASL for inclusion in the “Best of ILC” summary slide deck highlighting the most noteworthy contributions to the scientific program at this year’s meeting. The oral presentation at EASL entitled, “Multicenter, Double-blind, Placebo-controlled, Randomized Trial of Emricasan in Subjects with NASH Cirrhosis and Severe Portal Hypertension (PH),” (#LB01) detailed results from the company’s Phase 2b ENCORE-PH clinical trial of emricasan, the company’s first-in-class, orally active pan-caspase protease inhibitor.

  • GlobeNewswire

    Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference

    Conatus Pharmaceuticals Inc. (CNAT) has accepted an invitation to participate in the H.C. Wainwright Global Life Sciences Conference (April 7-9 in London). Conatus senior management will conduct a series of scheduled meetings with investment professionals and present a company overview on Tuesday, April 9, 2019, from 10:30 a.m. to 10:50 a.m. BST (5:30 a.m. to 5:50 a.m. EDT). Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need.

  • GlobeNewswire

    Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis

    The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement with no worsening of steatohepatitis compared with placebo at week 72. “Although emricasan did not have the desired effect in these earlier-stage NASH fibrosis patients, we believe its demonstrated biomarker activity across a broad spectrum of liver disease warrants continued evaluation in more advanced-stage NASH cirrhosis patients,” said Steven J. Mento, Ph.D., President, Chief Executive Officer and co-founder of Conatus.

  • GlobeNewswire

    Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

    The oral presentation at EASL entitled, “Multicenter, Double-blind, Placebo-controlled, Randomized Trial of Emricasan in Subjects with NASH Cirrhosis and Severe Portal Hypertension (PH),” (#LB01) will detail results from the company’s Phase 2b ENCORE-PH clinical trial of emricasan, the company’s first-in-class, orally active pan-caspase protease inhibitor. Guadalupe Garcia-Tsao, M.D., Professor of Medicine in the Section of Digestive Diseases at Yale School of Medicine, Director of the Clinical and Translational Core at Yale Liver Center, Chief of the Section of Digestive Diseases at the Veterans Administration-Connecticut Health Care System, and the central reader in the ENCORE-PH trial, will deliver the presentation on Saturday, April 13, at 4:00 p.m. CEST.

  • GlobeNewswire

    Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates

    SAN DIEGO, March 08, 2019 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2018, and.

  • GlobeNewswire

    Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results

    Conatus Pharmaceuticals Inc. (CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2018, after the market close on Friday, March 8, 2019. Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Friday, March 8, 2019, to discuss the financial results and provide a corporate update. A live and archived audio webcast of the call will also be available in the Investors section of the Conatus website at www.conatuspharma.com.

  • GlobeNewswire

    Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis

    Conatus Pharmaceuticals Inc. (CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial evaluating emricasan, the company’s first-in-class, orally-active pan-caspase inhibitor. “With screening in the ENCORE-LF clinical trial complete, we remain on track for clinical events as announced last quarter, with top-line results expected in mid-2019,” said David T. Hagerty, M.D., Executive Vice President of Clinical Development at Conatus. The ENCORE-LF clinical trial is designed to evaluate safety, dosing and efficacy of emricasan in patients with decompensated NASH cirrhosis as an integral part of the company’s initial registration strategy.

  • ACCESSWIRE

    Today's Research Reports on Trending Tickers: Voyager Therapeutics and Conatus Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / January 30, 2019 / U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The ...

  • GlobeNewswire

    Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials

    SAN DIEGO, Jan. 28, 2019 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced publications expanding on previously reported results from three of the company’s.

  • ACCESSWIRE

    Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis

    NEW YORK, NY / ACCESSWIRE / December 6, 2018 / U.S. markets fell in Tuesday amidst trade related uncertainty between the U.S. and China. The Dow Jones Industrial Average fell 3.10 percent to close at 25,027.07, ...

  • GlobeNewswire

    Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis

    Conatus Pharmaceuticals Inc. (CNAT) today announced top-line results from the company’s Phase 2b ENCORE-PH clinical trial showing clinically meaningful treatment effects in compensated NASH cirrhosis patients at high risk of decompensation. The trial’s primary endpoint was change in mean hepatic venous pressure gradient (HVPG) from baseline to Week 24 in any of three emricasan dosing groups compared with placebo. In the overall trial population, changes in HVPG from baseline to Week 24 showed trends consistently favoring emricasan compared with placebo but did not meet the primary endpoint.

  • GlobeNewswire

    Investor Expectations to Drive Momentum within 2U, Broadwind Energy, Nuverra Environmental Solutions, Ability, ContraFect, and Conatus Pharmaceuticals — Discovering Underlying Factors of Influence

    NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire

    Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting

    Poster #1226, “Multicenter, double-blind, randomized trial of emricasan in subjects post liver transplantation (LT) with recurrent hepatitis C virus (HCV) and liver fibrosis or cirrhosis despite achieving sustained virologic response (SVR),” will be displayed by Catherine Frenette, M.D., (Scripps Clinic, La Jolla, CA) in the Liver Transplantation: Viral Hepatitis section on Saturday, November 10, from 2:00 p.m. to 7:30 p.m. PT, in the Moscone Center Poster Hall – Hall C. Presentation #251A, highlighting selected content from poster #1226, will be delivered by K. Rajinder Reddy, M.D., (University of Pennsylvania Medical Center, Philadelphia, PA) in the Parallel 37: Liver Transplantation: Alcohol and Hepatitis C session on Monday, November 12, at 3:15 p.m. PT, in the Moscone Center Room 153/155.

  • ACCESSWIRE

    Today’s Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Titan Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 5, 2018 / Conatus Pharmaceuticals and Titan Pharmaceuticals were both seeing gains in Friday’s trading session. There was no news to explain Titan shares jumping but Conatus reported third quarter results and an update on its trials last week. Conatus Pharmaceuticals Inc. shares closed up 19.63% on about 1.8 million shares traded on Friday.

  • GlobeNewswire

    Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates

    SAN DIEGO, Nov. 01, 2018 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat.